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Background: Platelet reactivity is a well-established determinant of clinical outcomes
after percutaneous coronary intervention (PCI). Conflicting data have been reported
concerning the impact of chronic kidney disease (CKD) on residual platelet reactivity
(PR) on clopidogrel in patients with coronary artery disease (CAD) undergoing PCI. Aim
of the present study was to compare PR and its association with clinical outcomes after
PCI in CAD patients with and without CKD.
Methods: In 800 patients treated with clopidogrel we measured PR with the VerifyNow
P2Y12 Assay immediately before PCI (results given as P2Y12 reaction units [PRU]).
According to previous studies, we defined HPR as a PRU value 240 and LPR and a
PRU value 178. CKD was defined as a glomerular filtration rate 60 ml/min/1.73 m2.
Clinical follow-up at 30 days was obtained in all patients. Net adverse clinical events
(NACE) were considered as ischemic (death, myocardial infarction and target vessel
revascularization) and bleeding events (according to TIMI criteria).
Results: Patients with (n173, 21.6%) and without CKD showed similar PRU values
(20867 vs. 20775; p0.819). The incidence of 30-day ischemic (12.1% vs. 7.2%;
p0.036) and bleeding events (8.7% vs. 2.1%; p0.001) was higher in the CKD group.
The presence of HPR was associated with higher rates of ischemic events in both patients
with (21.1% vs. 7.6%; p0.012) and without CKD (12.6% vs. 4.7%; p0.001).
Likewise, LPR was associated with higher rates of bleeding in both patients with (19.3%
vs. 3.4%; p0.001) and without CKD (5.1% vs. 0.5%; p0.001). NACE were
significantly higher in CKD patients with HPR or LPR (25.4%) and lowest in those
without CKD, HPR or LPR (6.6%; p for trend 0.001). At multivariate analysis, the
combination of CKD with LPR or HPR was the strongest predictor of NACE (odds ratio
3.4, 95% confidence interval 2.0-5.6; p0.001).
Conclusions: We did not find an association between CKD and higher levels of residual
PR on clopidogrel. However, the combination of CKD with either high or low platelet
reactivity is a strong determinant of adverse events after PCI.
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Background: Acute kidney injury (AKI) is a potentially serious complication of
transcatheter aortic valve implantation (TAVI) that has recently been re-defined by the
Valve Academic Research Consortium (VARC). The aim of this study was to identify the
incidence and risk factors for AKI after TAVI.
Methods: We performed a retrospective analysis of data from 248 consecutive patients
undergoing TAVI using the Edwards bioprosthesis at St Thomas’ Hospital, London, UK.
AKI was defined as a VARC-modified Risk, Injury, Failure, Loss, and End-stage (RiFLE)
kidney disease score 2.
Results: Of 248 patients who underwent TAVI using the Edwards bioprosthesis 89
(35.9%) of patients suffered an acute kidney injury as defined by the a score of2 on the
VARC-modified RiFLE score. The overall mean pre-procedural creatinine was
116.669.3 mol/L with an overall peak creatinine of 148.894.4 mmol/L (p0.001).
Patients with AKI had greater mean pre-procedural (134.774.5 v. 106.564.2 mmol/L
(p0.001), 48h (206.889.1 v. 98.040.0 mmol/L (p0.001)) and 72h creatinine
concentrations (205.988.3 v. 99.339.6 mmol/L (p0.001)). A higher VARC-
modified RiFLE score was associated with increased mortality (p0.001). Kaplan Meier
analysis according to incidence of RiFLE score 2 (i.e. AKI) demonstrated significantly
increased mortality at 30 days (13.5% v. 3.8%), 1 year (31.5% v. 15.0%) and overall
(40.4% v. 19.5%; logrank p0.001) at a median follow up of 379 days (interquartile
range 113-729 days). Multivariate logistic regression analysis revealed that the variable
with the strongest independent association with risk of AKI was DM (OR 3.17, 95%CI
1.67-6.05, p0.001), followed by peripheral vascular disease (OR 2.54, 95%CI 1.34-
6.44, p0.007) and the pre-procedural stage of chronic kidney disease (OR 1.57, 95%CI
1.11-2.21, p0.010).
Conclusions: Greater than 1/3 of patients sustain AKI after TAVI using the Edwards
bioprosthesis, as defined by the VARC-modified RiFLE score. AKI was associated with
increased mortality at both 30-days and at 1-year. A history of diabetes mellitus,
peripheral vascular disease and higher chronic kidney disease stage had the strongest
independent associations with post-TAVI AKI.
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Background: Patients treated with renal failure have been reported having high
incidence of mortality and other complications rate after PCI. Optimal treatment of PCI
for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to
compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS),
Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting
stent (EES) on the outcome of percutaneous coronary intervention in renal failure patients
with dialysis (CRF-HD).
Methods: A prospective analysis of 1013 patients with CRF-HD (258 SES, 244 PES, 77
ECS, 118 ZES-R, 128 BES, 188 EES) in six high volume Asian centers after successful
stenting was performed. The study endpoints were 30 days major adverse cardiac events
(MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and MACE.
Results: The baseline clinical characteristics between 5 groups were similar. See table for
clinical results.
Conclusions: The use of drug-eluting stents in patient with CRF-HD was safe with low
acute complication. Patients treated with PES and EES showed lesser incidence of
restenosis rate and TLR compared with other drug-eluting stents.
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Background: Controversies persist whether statin pre-treatment can prevent contrast-
induced nephropathy(CIN). We evaluate the efficacy of high dose atorvastatin on CIN
occurrence.
Methods: We studied whether atorvastatin 80mg loading and subsequent use for 5days
(high dose group[HD]) could prevent CIN as compared to those received atorvastatin
10mg (routine dose group[RD]) with same schedule in patients with ST-elevation
myocardial infarction undergoing primary angioplasty. Primary endpoint was incidence of
CIN, defined as a  25% or  0.5 mg/dL increase in baseline serum creatinine within 5
days after contrast administration. Secondary endpoint was 1- and 6-month renal function
change and composite of all cause mortality, renal failure, heart failure and target vessel
revascularization.
Results: One hundred and ten patients were allocated to HD and 108 to RD from August
2007 to February 2009. CIN incidence was 5.5% (6/110) in HD and 10.2% (11/108) in
RD, a nonsignificant difference (p0.193). CIN occurred significantly less in HD than
RD, 0% vs. 16.7% (p0.024) in subgroups of renal insufficiency (creatinine clearance
[CrCl]60mL/min) and 4% (1/25) and 23.1% (6/26) respectively, (p0.048) in old
patients70. Composite of clinical outcomes at 6-month was comparable in HD and RD
(7.9% and 13.1%, p0.26). CrCl rat 1-month tended to be higher, in HD than in RD, 81
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